Cisplatin + Paclitaxel

Indication

Bladder cancer

• Paclitaxel 175 mg/m2 ivi (3h) d1
• Cisplatin 75 mg/m2 ivi (30 min) d1
• Repeat q3w

References

Dreicer R et al Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 2000 Mar;18(5):1058-61.

Cervical Cancer

Neoadjuvant chemotherapy

• Cisplatin 60 mg/m2 iv d1
• Paclitaxel (Taxol) 60 mg/m2 iv d1
• Every 10 days x 3 cycles

References

Park DC et al. Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. Gynecol Oncol 2004; 92:59

Chemotherapy for stage IVB (metastatic) cancer

• Cisplatin 50 mg/m2 iv d1
• Paclitaxel (Taxol) 135 mg/m2 iv d1
• Q3w

References

Moore, DH et al. Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. J Clin Oncol 2004; 22:3113

Endometrial Cancer

Chemotherapy for stage IVB (metastatic) cancer

• Cisplatin 75 mg/m2 iv d1
• Paclitaxel (Taxol) 175 mg/m2 iv d1
• Q3w

References

Dimopoulos, MA et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol 2000; 78:52

Esophageal Cancer

Chemotherapy for stage IV (metastatic) cancer

• Cisplatin 75 mg/m2 iv d2
• Paclitaxel (Taxol) 200 mg/m2 civi over 24hrs d1
• Q3w
• G-CSF support

References

Ilson, DH et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000; 6:316

Gastric Cancer

Chemotherapy for locally advanced unresectable and metastatic cancer

• Cisplatin 60 mg/m2 iv d1
• Paclitaxel (Taxol) 160 mg/m2 iv d1
• Q2w

References

Kornek, GV et al. Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br J Cancer 2002; 86:1858

Ovarian Epithelial Cancer

Adjuvant chemotherapy

• Cisplatin 75 mg/m2 iv over 30 min d1
• Paclitaxel (Taxol) 135-175 mg/m2 iv over 3 hrs d1
• Q3w x 6 cycles

References

Ozols, RF et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21:3194

Du Bois, A et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95:1320

Neijt, JP et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18:3084

Chemotherapy for recurrent or metastatic cancer

• Cisplatin 50 mg/m2 iv d1
• Paclitaxel (Taxol) 175 mg/m2 iv over 3 hrs d1
• Q3w

References

The ICON and AGO collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361:2099

Lung Cancer Non Small Cell

Chemotherapy for stage IV (metastatic) cancer

• Paclitaxel (Taxol) 175 mg/m2 iv day 1
• Cisplatin 75 mg/m2 iv day 2
• Q3w

References

Schiller JH et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Eng J Med 2002; 346:92